Skip to main content

Table 2 Immunohistochemical analysis

From: Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study

Items

Treatment groups

P value

Control (n = 10)

DOX (n = 11)

PDOX (n = 12)

Cat B

100% (10/10)

10% (11/11)

100% (12/12)

P > 0.05

VEGF

100% (10/10)

90.9% (10/11)

83.3% (10/12)

P > 0.05

E-cadherin

100% (10/10)

90.9% (10/11)

100% (12/12)

P > 0.05

Ki-67

77.1 ± 7.8%*

72.3 ± 4.9%#

61.6 ± 14.6%

*P < 0.05, Control vs PDOX #P < 0.05, DOX vs PDOX

CD34

47.2 (21.4-70.0)

60.9 (37.0-91.2)

55.6 (22.2-80.2)

P > 0.05

D2-40

0.5 (0.0-3.2)

1.8 (0.0-8.4)

1.8 (0.0-5.8)

P > 0.05

  1. Notes: Cat B, VEGF and E-cadherin were evaluated according to the percentage of positive expression (number of animals with positive expression ÷ number of all animals in the group × 100%). The expression of Ki-67 was evaluated according to positive rate in every animal. The positive expression of CD34 and D2-40 was evaluated according to microvessel density (MVD) and lymphatic microvessel density (LMVD).
  2. *, #: denote statistical significances for comparisons of the same item in different groups, as clearly described in the P value column.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us